Extended-Spectrum β-Lactamase을 생성하는 Escherichia Coli 감염에 의한 패혈증 1예 = A Case Report of Sepsis by Extended-Spectrum β-Lactamase Producing Escherichia Coli

다국어 초록 (Multilingual Abstract)

The overall prognosis of acute pyelonephritis is good, but the infections by extended spectrum β-lactamase (ESBL)producing Escherichia coli (E.coli) cause poor responses to empirical antibiotic treatment, and consequently increase mortality. ESBL can hydrolyze the antibiotics with a β-lactam ring and confer resistance to oxyimino-cephalosporins and monobactams. If the patient shows poor responses to empirical antibiotics or severe septic conditions, physicians must switch the antibiotics to other antibiotics covering resistant strains without delay. We report a case of acute pyelonephritis by extended-spectrum β-lactamase producing E.coli in a 29-year-old woman who was empirically treated with oral ciprofloxacin as an initial treatment, but progressed to sepsis.

국문 초록 (Abstract)

급성 신우신염은 신실질과 신우를 침범하는 비교적 흔한 감염성 질환으로 여성에서 호발한다. 급성 신우신염은 치료 경과와 예후는 양호한 편이나 초기에 항생제 투여가 적절해야 하며, 세균의 항생제 감수성 결과에 따라서 시기 적절하게 항생제를 변경하는 것도 경과에 중요한 영향을 미친다. 세계적으로 항생제에 내성을 갖는 세균이 증가하고 있으며, 요로 감염의 치료에 흔히 사용되는 ciprofloxacin에 대한 내성도우려된다. 게다가 extended-spectrum -lactamase을 생성하는Escherichia coli의 증가도 중증 감염의 위험 요인이 되고 있다.
저자들은 29세 여자 환자가 급성 신우신염을 진단 받고 경험적 항생제 치료를 받았으나 폐렴과 패혈증으로 진행된 증례를 보고한다. 본 증례를 통해 항생제 내성 감염균에 대한 경각심을 일깨우고 감염질환의 적절한 항생제 치료에 도움이 되고자 한다.

참고문헌 (Reference)

1 이진서, "최근 5년간 발생한 지역사회 획득성 급성 신우신염 환자의임상적 양상과 원인균 및 항생제 감수성에 대한 고찰" 대한신장학회 21 (21): 5-913, 2002

2 김지현, "지역사회획득 급성신우신염에서 Quinolone 항생제 내성" 대한신장학회 25 (25): 571-578, 2006

3 이하정, "지역사회 획득 급성 신우신염의 원인균 및 ciprofloxacin 저항성에 대한 연구" 대한신장학회 27 (27): 688-695, 2008

4 고지선, "대전지역에서 분리된 Escherichia coli 와 Klebsiella pneumoniae 의Extended-Spectrum -lactamase 생성 현황" 대한진단검사의학회 27 (27): 344-350, 2007

5 Robertson CM, "The systemic inammatory response syndrome" 8 : 1382-1389, 2006

6 Ronald A, "The etiology of urinary tract infection: traditional and emerging pathogens" 49 : 71-82, 2003

7 Ki M, "The epidemiology of acute pyelonephritis in South Korea, 1997-1999" 160 : 985-993, 2004

8 Safrin S, "Pyelonephritis in adult women: inpatient versus outpatient therapy" 85 : 793-798, 1988

9 Jung Min Kim, "Prevalence of CTX-M Extended-spectrum Beta-Lactamases in Clinical Isolates of Enterobacteriaceae in Korea" 대한미생물학회 34 (34): 303-310, 2005

10 Tumbarello M, "Predictors of mortality in patients with bloodstream infections caused by extended-spectrumbeta- lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment" 51 : 1987-1994, 2007

11 Endimiani A, "Optimizing therapy for infections caused by enterobacteriaceae producing extended-spectrum beta-lactamases" 28 : 646-655, 2007

12 Huang ES, "National patterns in the treatment of urinary tract infections in women by ambulatory care physicians" 162 : 41-47, 2002

13 Gupta K, "Increasing antimicrobial resistance and the management of uncomplicated communityacquired urinary tract infections" 135 : 41-50, 2001

14 Warren JW, "Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA)" 29 : 745-758, 1999

15 Paterson DL, "Extended-spectrum beta-lactamases: a clinical update" 18 : 657-686, 2005

16 Pitout JD, "Extended-spectrum beta-lactamaseproducing Enterobacteriaceae: an emerging public-health concern" 8 : 159-166, 2008

17 Rodriguez-Bano J, "Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients" 42 : 1089-1094, 2004

18 김창기, "Detection of CTX-M-Type Extended-Spectrum β-Lactamase in Clinical Isolates of Chromosomal AmpC β-Lactamase-Producing Enterobacteriaceae from Korea and Their Molecular Characteristics" 대한임상미생물학회 11 (11): 90-97, 2008

19 Talan DA, "Comparison of ciprooxacin (7 days) and trimethoprimsulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial" 283 : 1583-1590, 2000

20 Tan BH, "Community-acquired bacteremia with an ESBL-producing Escherichia coli strain: a case report" 6 : 318-319, 2002

21 Rodriguez-Bano J, "Clinical signicance of extendedspectrum beta-lactamases" 6 : 671-683, 2008

22 Fihn SD, "Clinical practice. Acute uncomplicated urinary tract infection in women" 349 : 259-266, 2003

23 Eom JS, "Clinical and molecular epidemiology of quinolone-resistant Escherichia coli isolated from urinary tract infection" 8 : 227-234, 2002

24 Huang JJ, "Chuang YC. Acute bacterial nephritis: a clinicoradiologic correlation based on computed tomography" 93 : 289-298, 1992

25 Schiappa DA, "Ceftazidime-resistant Klebsiellapneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation" 174 : 529-536, 1996

26 Tumbarello M, "Bloodstream infections caused by extended-spectrum-betalactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy" 52 : 3244-3252, 2008